You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Drug Sales Trends for PROAIR HFA


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for PROAIR HFA (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $31,932,951
INSIDE ANOTHER STORE $52,588,314
[disabled in preview] $378,624,180
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 300,501
INSIDE ANOTHER STORE 650,301
[disabled in preview] 5,120,550
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $337,445,730
MEDICARE $50,926,570
[disabled in preview] $75,146,225
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for PROAIR HFA
Drug Units Sold Trends for PROAIR HFA

Annual Sales Revenues and Units Sold for PROAIR HFA

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
PROAIR HFA ⤷  Try for Free ⤷  Try for Free 2022
PROAIR HFA ⤷  Try for Free ⤷  Try for Free 2021
PROAIR HFA ⤷  Try for Free ⤷  Try for Free 2020
PROAIR HFA ⤷  Try for Free ⤷  Try for Free 2019
PROAIR HFA ⤷  Try for Free ⤷  Try for Free 2018
>Drug Name >Revenues (USD) >Units >Year

Market Analysis and Sales Projections for ProAir HFA

Last updated: December 30, 2024

Overview of ProAir HFA

ProAir HFA is a metered-dose inhaler (MDI) containing albuterol sulfate, used for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. It is a crucial medication in the management of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)[2].

Current Market Scenario

Sales and Revenue

As of 2020, ProAir HFA had significant market presence, with gross sales for the previous 12 months approximating $1.4 billion, as measured by IQVIA. This figure highlights the substantial demand for this medication in the respiratory disease management market[2].

Generic Versions

The FDA approval of Perrigo's generic albuterol sulfate inhalation aerosol, an AB-rated generic version of ProAir HFA, marked a significant development. This generic version is expected to lower costs for consumers and payors, potentially altering market dynamics by increasing competition and accessibility[2].

Market Size and Growth

Historical Data

From 2015 to 2020, the sales of medical inhalers, including HFC MDIs like ProAir HFA, showed a steady increase. The total HFC propellant sold in MDIs in the United States grew from 827 metric tons in 2015 to 1,491 metric tons in 2020. This growth is indicative of the increasing demand for respiratory medications[1].

Projected Growth

The global inhalation and nasal spray generic drugs market, which includes albuterol-based products like ProAir HFA, is projected to grow at a CAGR of 8.56% from 2025 to 2030. This growth is driven by the increasing prevalence of respiratory diseases and the expanding generic drug market[3].

Segment Analysis

Drug Class and Indication

ProAir HFA falls under the category of short-acting beta-agonists (SABAs), which are widely used for quick relief in asthma and COPD. The market for SABAs is expected to grow due to the rising incidence of respiratory diseases and the preference for these medications among both patients and healthcare providers[5].

Patient Demographics

The patient demographics for ProAir HFA include individuals aged 4 years and older suffering from reversible obstructive airway disease. The growing population and increasing awareness of respiratory diseases are expected to expand this demographic, driving market growth[2].

Distribution Channels

The distribution channels for ProAir HFA include retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment has shown a growth rate of 11.7% over recent years, indicating a strong retail market presence for such medications[4].

Competitive Landscape

Branded vs. Generic

The approval of generic versions of ProAir HFA is expected to increase competition in the market. However, branded versions like ProAir HFA still maintain a significant market share due to brand loyalty and the trust associated with established pharmaceutical companies[2].

Technological Advancements

The introduction of smart inhalers, which can track adherence and provide real-time data, is also influencing the market. While these smart inhalers are not direct competitors to traditional MDIs like ProAir HFA, they represent a trend towards more sophisticated and patient-centric respiratory disease management tools[4].

Regulatory Environment

FDA Approvals

The FDA approval process for generic versions of ProAir HFA and other respiratory medications is stringent but crucial for market entry. The approval of Perrigo's generic albuterol sulfate inhalation aerosol sets a precedent for future generic entries, which could impact the market share of branded products[2].

Environmental Considerations

The use of hydrofluorocarbons (HFCs) in MDIs like ProAir HFA has environmental implications. Research into alternative propellants such as HFO-1234ze(E) and HFC-152a is ongoing, which may influence future product formulations and market dynamics[1].

Key Drivers and Opportunities

Increasing Prevalence of Respiratory Diseases

The rising prevalence of asthma, COPD, and other respiratory diseases drives the demand for medications like ProAir HFA. This trend is expected to continue, fueled by lifestyle changes, environmental factors, and better diagnostic techniques[5].

Growing Awareness and Diagnosis

Improved awareness and diagnosis of respiratory diseases lead to more patients being prescribed albuterol-based medications. This increased diagnosis rate is a significant driver for the market growth of ProAir HFA and its generic counterparts[5].

Combination Therapies

The development of combination therapies that include albuterol along with other medications offers opportunities for market expansion. These combination therapies can provide enhanced efficacy and convenience, appealing to both healthcare providers and patients[5].

Sales Projections

Short-Term Projections

Given the steady growth in the sales of HFC MDIs and the increasing demand for respiratory medications, ProAir HFA and its generic versions are expected to maintain a strong market presence in the short term. The market is projected to grow at a rate aligned with the overall growth in the respiratory disease management sector[1].

Long-Term Projections

By 2030, the global albuterol market, which includes ProAir HFA and its generic versions, is expected to reach a value of USD 7984.37 million, growing at a CAGR of 6.80% from 2022 to 2030. This growth will be driven by the increasing prevalence of respiratory diseases, growing awareness, and advancements in healthcare[5].

Key Takeaways

  • Market Growth: The market for ProAir HFA and its generic versions is expected to grow driven by the increasing prevalence of respiratory diseases.
  • Generic Competition: The entry of generic versions will increase competition but also make the medication more accessible.
  • Technological Advancements: Smart inhalers and combination therapies are emerging trends that could influence market dynamics.
  • Regulatory Environment: FDA approvals and environmental considerations will shape the future of HFC-based MDIs.
  • Sales Projections: The market is projected to grow significantly by 2030, driven by demographic and healthcare trends.

FAQs

Q: What is ProAir HFA used for? A: ProAir HFA is used for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Q: Has a generic version of ProAir HFA been approved? A: Yes, Perrigo's generic albuterol sulfate inhalation aerosol, an AB-rated generic version of ProAir HFA, has been approved by the FDA.

Q: What are the key drivers for the growth of the ProAir HFA market? A: The increasing prevalence of respiratory diseases, growing awareness and diagnosis, and lifestyle changes are key drivers.

Q: How is the market for ProAir HFA expected to grow in the long term? A: The market is expected to grow at a CAGR of 6.80% from 2022 to 2030, reaching a value of USD 7984.37 million by 2030.

Q: What are the potential impacts of smart inhalers on the ProAir HFA market? A: Smart inhalers could influence market dynamics by providing more sophisticated and patient-centric respiratory disease management tools, though they are not direct competitors to traditional MDIs like ProAir HFA.

Sources

  1. EPA: Market Characterization of the U.S. Metered Dose Inhaler Industry[1].
  2. Perrigo & Catalent: FDA Approval of Perrigo's AB-rated Generic Version of ProAir HFA[2].
  3. Grand View Research: Inhalation And Nasal Spray Generic Drugs Market Report 2030[3].
  4. Global Market Insights: Smart Inhalers Market value to cross 260 million by 2025[4].
  5. Data Bridge Market Research: Global Albuterol Market – Industry Trends and Forecast to 2030[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.